General description

A methyl ester prodrug of in vitro active N-hydroxybutenoic acid compound (Cat. No. 420202) that is shown to preferentially induce hypermethylation of histone proteins (EC₅₀ for H3K4me3 and H3K9me3 = 10.3 and 8.6 µM in KYSE150 cells, and 6.7 and 6.3 µM in MCF7 cells, respectively), and arrests cell growth. Acts as a selective inhibitor of Jumonji domain-containing histone demethylases (JHDMs) over prolyl hydroxylases (PHDs), and prevents myogenesis through inhibition of H3K27 demethylase UTX in C2C12 cells at 2 µM.

A methyl ester prodrug of in vitro active N-hydroxybutenoic acid compound (Cat. No. 420202) that is shown to preferentially induce hypermethylation of histone proteins (EC₅₀ for H3K4me3 and H3K9me3 = 10.3 and 8.6 µM in KYSE150 cells, and 6.7 and 6.3 µM in MCF7 cells, respectively), and arrests cell growth. Acts as a selective inhibitor of Jumonji domain-containing histone demethylases (JHDMs) over prolyl hydroxylases (PHDs), and prevents myogenesis through inhibition of H3K27 demethylase UTX in C2C12 cells at 2 µM.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Luo, X., et al. 2011. J. Am. Chem. Soc.133, 9451.

Packaging

Packaged under inert gas

10 mg in Glass bottle

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Standard Handling (A)